Published in Nature on August 03, 1973
The effects of the immunologic release of histamine upon human lung cyclic nucleotide levels and prostaglandin generation. J Clin Invest (1978) 1.30
Histamine production during the anti-allograft response. Demonstration of a new lymphokine enhancing histamine synthesis. J Exp Med (1981) 1.22
Effects of histamine on monocyte complement production. I. Inhibition of C2 production mediated by its action on H2 receptors. Clin Exp Immunol (1980) 1.19
Guanosine 3',5'-monophosphate and adenosine 3',5'-monophosphate content of human umbilical artery. J Clin Invest (1975) 1.03
Pharmacologic modulation of inflammatory mediator release by rat mast cells. Am J Pathol (1976) 1.00
Decreased H2 histamine response of granulocytes of asthmatic patients. J Clin Invest (1977) 0.97
Effect of histamine on monocyte complement production. II. Modulation of protein secretion, degradation and synthesis. Clin Exp Immunol (1980) 0.96
Antigen-specific mast cell degranulation in contact sensitivity to picryl chloride. An early event. Immunology (1980) 0.93
Histamine receptors on guinea-pig alveolar macrophages: chemical specificity and the effects of H1- and H2-receptor agonists and antagonists. Clin Exp Immunol (1979) 0.90
Arterial plasma histamine levels at rest, and during and after exercise in patients with asthma: effects of terbutaline aerosol. Thorax (1981) 0.89
Effects of H1- and H2-receptor blocking agents on histamine-induced bronchoconstriction in non-asthmatic subjects. Br J Clin Pharmacol (1979) 0.89
A species comparison of the histamine H2-receptor on mast cells and basophils. Agents Actions (1982) 0.88
Evidence for H2-receptor-mediated inhibition of histamine release from isolated rat mast cells. Agents Actions (1982) 0.85
H2 receptor blockade and bronchial hyperreactivity to histamine in asthma. Thorax (1981) 0.83
The effects of metiamide and H1 receptor blocking agents on anaphylactic response in guinea-pigs. Agents Actions (1979) 0.82
Proceedings: Inhibition by antigen and by histamine antagonists of the uptake of histamine by isolated human leucocytes. Br J Pharmacol (1976) 0.81
A new in vivo method for the measurement of repetitive anaphylactic responses in the guinea-pig. Br J Pharmacol (1984) 0.80
Effects of histamine agonists and antagonists on luminol-dependent chemiluminescence of granulocytes. Agents Actions (1984) 0.78
The effects of metiamide on cell-mediated immune reactions in the guinea-pig. Br J Pharmacol (1977) 0.78
Fast deactivation of guinea-pig isolated ileum to C5adesArg: a possible cyclic AMP-dependent mechanism. Br J Pharmacol (1985) 0.78
The human lung mast cell. Environ Health Perspect (1984) 0.78
Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med (2012) 0.78
The antianaphylactic action of histamine H2-receptor agonists in the guinea-pig isolated heart. Br J Pharmacol (1987) 0.77
Effect of purine nucleotides and other compounds on the uptake of histamine and histidine. Agents Actions (1982) 0.77
Histamine1--histamine2 antagonism: effect of combined clemastine and cimetidine pretreatment on allergen and histamine-induced reactions of the guinea pig lung in vivo and in vitro. Agents Actions (1982) 0.76
Respiratory symptoms related to work in a factory manufacturing cimetidine tablets. Br Med J (Clin Res Ed) (1984) 0.76
Histamine and the pathogenesis of duodenal ulcer disease. Gut (1985) 0.75
H2-receptor blockade and exercise-induced asthma. Br J Clin Pharmacol (1984) 0.75
A modulation of the anaphylactic basophil histamine release by selective H2 histamine agonists. Agents Actions (1981) 0.75
Analysis of 3H-histamine interaction with lymphocytes: receptor binding or uptake? Clin Exp Immunol (1983) 0.75
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Anaphylaxis. N Engl J Med (1991) 2.53
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene (2009) 1.89
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
A bundle of care to reduce colorectal surgical infections: an Australian experience. J Hosp Infect (2011) 1.65
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Histamine release from rat peritoneal mast cells: inhibition by colchicine and potentiation by deuterium oxide. J Pharmacol Exp Ther (1968) 1.57
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Allergy to insect stings. II. Phospholipase A: the major allergen in honeybee venom. J Allergy Clin Immunol (1976) 1.45
The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol (1975) 1.45
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45
Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol (1991) 1.45
Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol (1994) 1.44
Kinins are generated during experimental rhinovirus colds. J Infect Dis (1988) 1.44
Properties of a subpopulation of T cells bearing histamine receptors. J Clin Invest (1975) 1.43
Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis (1988) 1.43
Immunotherapy of pollinosis in children: investigation of the immunologic basis of clinical improvement. N Engl J Med (1969) 1.42
Studies on the mechanism of hypersensitivity phenomena. XI. The effect of normal human serum on the release of histamine from human leukocytes by ragweed pollen antigen. J Immunol (1966) 1.41
Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis. Clin Exp Allergy (1993) 1.41
Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest (1983) 1.41
Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis (1990) 1.40
Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med (1981) 1.40
Induction of histamine secretion by polycations. Biochim Biophys Acta (1980) 1.39
Colchicine binding in tissue slices. Decrease by calcium and biphasic effect of adenosine-3', 5'-monophosphate. J Cell Biol (1971) 1.39
Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis (1991) 1.38
Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med (1984) 1.38
Heterogeneity of human mast cells. J Immunol (1983) 1.37
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37
Insect allergy: the state of the art. J Allergy Clin Immunol (1979) 1.35
Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol (1995) 1.33
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33
Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32
Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE. J Immunol (1987) 1.32
Recombinant IL-3 induces histamine release from human basophils. J Immunol (1989) 1.31
Studies on the mechanism of lymphocyte-mediated cytolysis. 3. The role of microfilaments and microtubules. J Immunol (1973) 1.31
Allergy to insect stings. I. Diagnosis of IgE-mediated hymenoptera sensitivity by venom-induced histamine release. J Allergy Clin Immunol (1974) 1.30
A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol (1968) 1.28
Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol (1986) 1.28
Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.27
A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med (1971) 1.27
Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol (1999) 1.26
Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med (1996) 1.25
In vitro reversed anaphylaxis: characteristics of anti-IgE mediated histamine release. Immunology (1970) 1.24
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J Clin Invest (1989) 1.23
IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. J Immunol (1994) 1.23
Eosinophil chemotactic factor (ECF). II. Release from human polymorphonuclear leukocytes during phagocytosis. J Immunol (1976) 1.22
Release of eosinophil chemotactic factor from human polymorphonuclear neutrophils by calcium ionophore A23187 and phagocytosis. Nature (1975) 1.21
Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis (1988) 1.21
Hyperosmolar triggering of histamine release from human basophils. J Clin Invest (1981) 1.21
Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol (1981) 1.21
Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest (1979) 1.20
Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization. J Clin Invest (1979) 1.20